BioLineRx (BLRX) Tops Q2 EPS by 14c

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of $0.00, $0.14 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.39 million versus the consensus estimate of $2.94 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• U.S. sees 80%-85% chance Iran deal will be signed - Bloomberg
• Precipio seeks shareholder votes to meet quorum for annual meeting